GET DAILY SIGNALSEMR vs LECO: Contrasting Two Industrial Automation Names
Key Takeaways
- Tickeron AI Verdict: LECO emerges as the favored name here, driven by stronger recent momentum and more visible near-term catalysts.
- EMR operates as a larger, software-oriented automation leader with a solid backlog, though near-term sales growth shows more mixed signals.
- LECO has posted accelerating, record-setting results fueled by automation and data center demand.
- Both companies stand to benefit from broader industrial and automation trends, yet their market positions and risk profiles vary in meaningful ways.
- Further details are available through EMR Major News and EMR Today's Price Move, along with LECO Major News and LECO Today's Price Move.
- To examine how AI assesses setups of this type, the Trending AI Robots section offers additional perspective.
Setting the Context for EMR and LECO
EMR and LECO are established industrial technology companies operating at the crossroads of manufacturing, automation, and electrification, though they serve quite different segments. This comparison matters for investors considering a large-cap automation and software business against a mid-cap welding and automation specialist showing notable recent strength. Reviewing their performance, positioning, and growth drivers can clarify which profile aligns better with individual goals in the present environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare within the broader industry.
EMR’s Business and Recent Results
EMR, based in St. Louis, focuses on automation and software solutions for process, hybrid, and discrete industries. Its offerings include intelligent devices, control systems, software, and test and measurement tools, with increasing attention on software annual contract value. Recent reports show resilient orders and margin expansion, supported by strength in power, semiconductors, and aerospace and defense. That said, underlying sales growth has been more moderate amid softness in Europe and China plus geopolitical issues in the Middle East. Management raised full-year earnings guidance, pointing to a strong backlog and expectations for a firmer second half. From what I see, the software emphasis provides some stability here.
LECO’s Business and Recent Results
LECO, headquartered in Cleveland, specializes in welding, cutting, and brazing products along with a growing automation segment. Recent performance has been robust, with record quarterly sales reflecting double-digit organic growth, broad volume gains, and a record order backlog. Automation revenue grew at a high-teens rate, aided by recovering industrial production, data center projects, and automotive launches. Management lifted full-year sales guidance, though input-cost inflation and supply-chain factors have pressured gross margins. The company also increased its dividend for the 31st straight year. One thing that stands out is the consistent execution on the automation side.
Head-to-Head Differences
The companies differ notably in scale, model, and growth trajectory. EMR is a diversified, software-focused automation player with higher-margin recurring revenue and a large backlog, yet near-term sales growth faces regional and geopolitical constraints. LECO is a more concentrated, cyclical welding business where automation and data-center exposure are driving accelerating volumes and record outcomes, even as margins contend with input costs. Sector exposure also varies: EMR leans toward process automation, energy, and industrial software, while LECO ties more directly to manufacturing, fabrication, and automotive spending. Risk profiles reflect this: EMR faces execution and geopolitical considerations, whereas LECO contends with greater cyclicality and commodity sensitivity. I reviewed relative positioning through Tickeron’s AI Trend Prediction Engine as part of this analysis.
Current AI Assessment
Considering factors such as trend consistency, earnings momentum, catalyst visibility, and relative positioning, the AI evaluation currently favors LECO. Record results, double-digit organic growth, a record backlog, and generally positive analyst revisions point to more consistent near-term momentum compared with EMR. The assessment remains probabilistic, however, and each stock carries its own advantages depending on risk tolerance and investment horizon. I’m watching this closely for any shifts in the data.
Using AI Tools for Trading Ideas
In my research process, I regularly look at Tickeron’s marketplace of AI Trading Bots. These systems track thousands of tickers across different strategies, timeframes, and performance metrics. The Trending AI Robots section narrows the list to those best aligned with current market conditions, providing a practical way to surface data-driven ideas for names like these. It serves as one useful reference point when building systematic approaches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EMR in upward trend: 10-day moving average broke above 50-day moving average on September 29, 2026
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on EMR as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for EMR just turned positive on October 27, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
Following a +2.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 217 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 150 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 17 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 30 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.515) is normal, around the industry mean (4.038). P/E Ratio (35.935) is within average values for comparable stocks, (37.928). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.013) settles around the average of (0.030) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery
Advertisement